KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

West Pharmaceutical Services (WST) Revenue (2016 - 2025)

West Pharmaceutical Services' Revenue history spans 17 years, with the latest figure at $805.0 million for Q4 2025.

  • For Q4 2025, Revenue rose 7.51% year-over-year to $805.0 million; the TTM value through Dec 2025 reached $3.1 billion, up 6.25%, while the annual FY2025 figure was $3.1 billion, 6.25% up from the prior year.
  • Revenue for Q4 2025 was $805.0 million at West Pharmaceutical Services, roughly flat from $804.6 million in the prior quarter.
  • Across five years, Revenue topped out at $805.0 million in Q4 2025 and bottomed at $670.7 million in Q1 2021.
  • The 5-year median for Revenue is $727.2 million (2021), against an average of $731.8 million.
  • The largest annual shift saw Revenue soared 37.25% in 2021 before it fell 6.86% in 2024.
  • A 5-year view of Revenue shows it stood at $730.8 million in 2021, then dropped by 3.02% to $708.7 million in 2022, then grew by 3.29% to $732.0 million in 2023, then grew by 2.3% to $748.8 million in 2024, then rose by 7.51% to $805.0 million in 2025.
  • Per Business Quant, the three most recent readings for WST's Revenue are $805.0 million (Q4 2025), $804.6 million (Q3 2025), and $766.5 million (Q2 2025).